{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:57:24Z","timestamp":1786982244886,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002649","name":"Yeungnam University","doi-asserted-by":"publisher","award":["2022"],"award-info":[{"award-number":["2022"]}],"id":[{"id":"10.13039\/501100002649","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12072-023-10517-w","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T12:02:29Z","timestamp":1681732949000},"page":"626-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease"],"prefix":"10.1007","volume":"17","author":[{"given":"Min Kyu","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Rim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Young","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Oh","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5472-4731","authenticated-orcid":false,"given":"Jung Gil","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"10517_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3350\/cmh.2021.0178","volume":"27","author":"SH Kang","year":"2021","unstructured":"Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, et al. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27:363\u2013401","journal-title":"Clin Mol Hepatol"},{"key":"10517_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gtc.2019.09.007","volume":"49","author":"MD Muthiah","year":"2020","unstructured":"Muthiah MD, Sanyal AJ. Burden of disease due to nonalcoholic fatty liver disease. Gastroenterol Clin North Am. 2020;49:1\u201323","journal-title":"Gastroenterol Clin North Am"},{"key":"10517_CR3","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2021","unstructured":"Toh JZK, Pan XH, Tay PWL, Ng CH, Yong JN, Xiao J, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2021;20:2462\u20132473","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10517_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686\u2013690","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10517_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10517_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3350\/cmh.2021.0067","volume":"27","author":"SH Kang","year":"2021","unstructured":"Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW, Korean NSG. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: big wave or ripple? Clin Mol Hepatol. 2021;27:257\u2013269","journal-title":"Clin Mol Hepatol"},{"key":"10517_CR7","doi-asserted-by":"crossref","unstructured":"Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(619\u2013629): e7","DOI":"10.1016\/j.cgh.2021.11.038"},{"issue":"2172\u20132181","key":"10517_CR8","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(2172\u20132181): e2176","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10517_CR9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1111\/liv.14828","volume":"41","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41:1290\u20131293","journal-title":"Liver Int"},{"issue":"2138\u20132147","key":"10517_CR10","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(2138\u20132147): e2110","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10517_CR11","first-page":"1761","volume":"114","author":"MJ Budoff","year":"2006","unstructured":"Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging. Council Clin Cardiol Circ. 2006;114:1761\u20131791","journal-title":"Council Clin Cardiol Circ"},{"key":"10517_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jacc.2018.05.027","volume":"72","author":"P Greenland","year":"2018","unstructured":"Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. Coronary Calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72:434\u2013447","journal-title":"J Am Coll Cardiol"},{"key":"10517_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.jacc.2010.06.038","volume":"56","author":"JW McEvoy","year":"2010","unstructured":"McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal RS, et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. J Am Coll Cardiol. 2010;56:1613\u20131622","journal-title":"J Am Coll Cardiol"},{"key":"10517_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/gutjnl-2016-311854","volume":"66","author":"DH Sinn","year":"2017","unstructured":"Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017;66:323\u2013329","journal-title":"Gut"},{"key":"10517_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4093\/dmj.2011.35.6.561","volume":"35","author":"SW Oh","year":"2011","unstructured":"Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J. 2011;35:561\u2013566","journal-title":"Diabetes Metab J"},{"key":"10517_CR16","doi-asserted-by":"crossref","unstructured":"Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62\u201369. https:\/\/doi.org\/10.2337\/dc10-S062.","DOI":"10.2337\/dc10-S062"},{"key":"10517_CR17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334\u20131357","journal-title":"Hypertension"},{"key":"10517_CR18","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American heart association\/national heart, lung, and blood institute scientific statement. Circulation. 2005;112:2735\u20132752","journal-title":"Circulation"},{"key":"10517_CR19","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hep.24105","volume":"53","author":"ZH Lin","year":"2011","unstructured":"Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726\u2013736","journal-title":"Hepatology"},{"key":"10517_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13764","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res. 2022;52(6):497\u2013507. https:\/\/doi.org\/10.1111\/hepr.13764","journal-title":"Hepatol Res"},{"key":"10517_CR21","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/liv.14675","volume":"40","author":"S Yamamura","year":"2020","unstructured":"Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40:3018\u20133030","journal-title":"Liver Int"},{"key":"10517_CR22","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388\u20131402","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10517_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u2013357","journal-title":"Hepatology"},{"key":"10517_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/hep.25593","volume":"56","author":"D Kim","year":"2012","unstructured":"Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56:605\u2013613","journal-title":"Hepatology"},{"key":"10517_CR25","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/gutjnl-2018-317666","volume":"68","author":"Y Chang","year":"2019","unstructured":"Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. 2019;68:1667\u20131675","journal-title":"Gut"},{"key":"10517_CR26","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41598-020-57894-y","volume":"10","author":"SH Kim","year":"2020","unstructured":"Kim SH, Park HY, Lee HS, Jung KS, Lee MH, Jhee JH, et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Sci Rep. 2020;10:1025","journal-title":"Sci Rep"},{"key":"10517_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res. 2021;51:1115\u20131128","journal-title":"Hepatol Res"},{"key":"10517_CR28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/eurheartj\/ehx448","volume":"39","author":"C Lassale","year":"2018","unstructured":"Lassale C, Tzoulaki I, Moons KGM, Sweeting M, Boer J, Johnson L, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018;39:397\u2013406","journal-title":"Eur Heart J"},{"key":"10517_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15015","volume":"48","author":"J Ampuero","year":"2018","unstructured":"Ampuero J, Aller R, Gallego-Duran R, Banales JM, Crespo J, Garcia-Monzon C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48:1260\u20131270","journal-title":"Aliment Pharmacol Ther"},{"key":"10517_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71:808\u2013819","journal-title":"Hepatology"},{"key":"10517_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61:1547\u20131554","journal-title":"Hepatology"},{"key":"10517_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/apt.15660","volume":"51","author":"JB Henson","year":"2020","unstructured":"Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51:728\u2013736","journal-title":"Aliment Pharmacol Ther"},{"key":"10517_CR33","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.cgh.2018.07.039","volume":"17","author":"MC Moreno-Del Castillo","year":"2019","unstructured":"Moreno-Del Castillo MC, Sanchez-Rodriguez A, Hernandez-Buen Abad JJ, Aguirre-Valadez J, Ruiz I, Garcia-Buen Abad R, et al. Importance of evaluating cardiovascular risk and hepatic fibrosis in patients with newly diagnosed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:997\u2013999","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2324\u20132331","key":"10517_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"F Baratta","year":"2020","unstructured":"Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol. 2020;18(2324\u20132331): e2324","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10517_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/diagnostics10030129","volume":"10","author":"T Niikura","year":"2020","unstructured":"Niikura T, Imajo K, Ozaki A, Kobayashi T, Iwaki M, Honda Y, et al. Coronary artery disease is more severe in patients with non-alcoholic steatohepatitis than fatty liver. Diagnostics (Basel). 2020;10:129","journal-title":"Diagnostics (Basel)"},{"key":"10517_CR36","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.16324","volume":"53","author":"JG Park","year":"2021","unstructured":"Park JG, Jung J, Verma KK, Kang MK, Madamba E, Lopez S, et al. Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;53:1030\u20131037","journal-title":"Aliment Pharmacol Ther"},{"key":"10517_CR37","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB Sr, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology\/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2935\u20132959","journal-title":"J Am Coll Cardiol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10517-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10517-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T15:26:35Z","timestamp":1702221995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10517-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10517"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10517-w","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RL serves as a consultant for Aardvark Therapeutics, Altimmune, Anylam\/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharm, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, and Viking Therapeutics. In addition, his institution has received grant support from Allergan, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Intercept, Inventiva, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer, and Sonic Incytes. He is also co-founder of Liponexus, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki as revised in 2013. The study protocol was approved by the institutional review board of the study center (IRB No. KNUH-2021-07-057-001). The requirement for informed consent from the study participants was waived by the ethics committee because of the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}